Drug Profile
Research programme: influenza vaccines - AstraZzeneca/Novartis
Latest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator Novartis
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 15 Aug 2011 Discontinued for Influenza virus infections in Switzerland (unspecified route)